IMMX Gains Momentum as CAR‑T Landscape Heats Up
$IMMX momentum continues >Mizuho analyst initiates $14 PT >Lily acquisition of Orna Therapeutics $2.4 billion >AbbVie acquired Capstan Therapeutics $2.1 billion CAR-T heating up >Next milestone: imminent enrollment completion >Could NXC-201 be an eventual front-line therapy for AL Amyloidosis? >BLA submission projected Q3’26 https://t.co/cPpiiFHQal
CMPS Leads Psychedelic Push; HELP Gains Momentum
$CMPS first-in-line for potential psychedelic approval for Treatment Resistant Depression (TRD) . Likely war between "Old School FDA" and MAHA movement. Will be exciting to see the outcome. $HELP with strong data for Major Depressive Disorder (MDD) and Breakthrough Therapy Designation. New...
Capital Markets Reshape Translational Therapeutics Landscape
The Catalyst Machine | Ep. 931 How Capital Markets Quietly Rewired Translational Therapeutics https://t.co/lWNRxW0wuQ https://t.co/l14X2JfrLX
All Pharma Will Secure Chinese Clinical Development Partner Soon
Within the next 18-24 months every Pharma will have a partner to access the China fast clinical development engine https://t.co/zpLV1XJbvB https://t.co/h5CyXUNO82
IMMX Poised for Rise After Feb ’26 Enrollment Completion
$IMMX looks like it wants to move higher. Enrollment completion in Feb ’26 is the next key catalyst, setting up the path toward a filing-grade dataset in AL amyloidosis. Market starting to sniff it out. Check out the AL Amyloidosis success story here: https://t.co/1ei6kat25y
Undercutting Patents Erodes Funding for Medical Breakthroughs
Novo Nordisk spent billions developing GLP-1s. HIMS spent… a legal memo. Undercutting patented drugs while ignoring IP protections isn’t disruption... it’s erosion of the system that funds medical breakthroughs. 🔗 https://t.co/s63Kx8jBMf
BCMA CAR‑T Shows Near‑Perfect Response in AL Amyloidosis
BCMA CAR-T in AL amyloidosis is starting to look like a real category, not a case report. The Alpha: • Efficacy: 100% hematologic response rate, 78% CR • Durability: 100% PFS and OS at 12 months in a heavily pretreated cohort (median...
Biopharma Sentiment Surges, Fueling M&A and IPO Boom
Biopharma sentiment just snapped higher $XBI BPSI index jumped 78 to 90 in Q1. That is not a grind. That is a turn. Under the hood: >Current Conditions surged 58 to 75. Pain is easing now, not someday. >12-month Expectations hit 100 for the first...
CT‑388 Dual GLP‑1/GIP Shows Potent, Durable Weight Loss
Didn’t know $RHHBY was in obesity? They are. Genentech’s CT-388 (dual GLP-1/GIP) showed Ph2 data (n=469) & it might be differentiated (TBD): >48w: −22.5% PBO-adj (efficacy est) / −18.3% treatment-regimen >BMIpreDM to normoglycemia: 73% vs 7.5% >d/c: 5.9% vs 1.3% >No plateau; clear dose-response 💡Mechanistic...
Deal Flow Quality Trumps Picking Skill for VC Success
Deal Flow Quality beats “picking skill” The figure below is a reminder that most VC chest-thumping is aimed at the wrong variable. In venture, outcomes are driven by two levers: >Pool quality (base rate): how many real winners exist in what you see >Picking...
Five 2026 Biotech Black Swans Threaten Industry Stability
🧨 5 Potential Black Swan Biotech Events in 2026 Low probability. Massive impact. Worth thinking about. 😲Multiple deaths from incorrect AI health advice One high-profile event could trigger lawsuits, regulation, and an overnight sentiment flip on AI-in-healthcare. 😲Sudden safety, supply, or reimbursement shock...
AI Could Slash Primary Care to $5 Copay
Predictions for the future of AI - the one that catches my attn most is the $5 copay Today; You wake up with a sore throat and grab the first primary care slot you can find. Ten minutes with a rushed clinician...
Biotech Shifts: New Masks, Diversification, AI‑Driven Trials
A few key takeaways from this week’s top biotech news: $BMY & $JANX: Tackling T-cell toxicity with tumor-activated masks. $PFE & $NVAX: Diversifying beyond mRNA for strategic risk hedging. $JNJ: projecting >$100B revenue post-Stelara patent cliff. $RHHBY: Building manufacturing moats for obesity market dominance. FDA:...
AI-Designed Drugs Double Phase‑I Success Rate
Phase I AI-discovered molecules show an 80-90% success rate in Ph1-to-Ph2 transition. *vs historic benchmark ~50% https://t.co/rC03gNjOPo https://t.co/AcK2XxfrW0
Progress in Cancer Fight, Yet GBM, Colorectal, Liver
Great progress update on the war on cancer “GBM, colorectal and liver still look very challenging...” See below for detail point down 👇🏼 https://t.co/UTFZSsDVcX
CORT Shows 30% Pre‑market
$CORT +30% pre-market Still room to run? >OS met: HR 0.65 (-35% death risk), mOS 16.0 vs 11.9 mo (+4.1) >PFS (prior): HR 0.70 (-30%) >n=381, safety ≈ control, no biomarker needed What’s next: full dataset at a med meeting; FDA PDUFA Jul 11, 2026...
CRVS Shows Promising AD Efficacy, Needs Tissue Validation
$CRVS +57% premarket on AD Cohort-4: randomized PBO-controlled signal (EASI-75 75%, mean EASI −72% vs −40% PBO; p=0.035) with clean safety, real but fragile (n=12 vs 12; 10 PBO-evaluable). 📝No skin-biopsy disclosed. While exiting progress serum PD != tissue reversal....
Biotech Success Now Hinges on De‑risking and Speed
We asked the biotwit some interesting industry questions. The answers were telling... 5 takeaways from last week’s biotech polls: 1️⃣ When efficacy ceilings are hit, risk wins. Safety, tolerability, and long-term risk profile now beat novelty and precision once drugs work “well enough.” 2️⃣...
IBRX Surge Fueled by 700% Revenue Forecast, Not Anecdote
$IBRX is trending on the TL - but the +40% pop more likely driven by prelim 2025 net product revenue of ~$113M, up ~700% y/y and not this tiny N CD19 CAR-NK + ritux anecdote in a rare lymphoma. https://t.co/64wkMTGX9v
Mega‑Fund Returns Require Unrealistic Share of Biotech Exit Pie
The Mega-Fund Math vs Reality Below is a simple case study on fund math. People are asking if a16z can really do a 3-5x on a $15B fund. To 3x net on $15B, you need ~$45B back. Assume ~5% ownership at exit. 👉 That...
Gene Therapy Leads Durable Clinical Value in Five Years
Which modality has the cleanest path to durable clinical value over the next 5 years?
Acute Infections May Reopen Investment Door for Anti‑Infectives
1/ The Back Door Is Open How Acute Infection Could Make Anti-Infectives Investable Again Anti-infectives never died. The business model did. Low prices. Short courses. High resistance risk. Pharma walked. Now look at Alfasigma stepping into HSV encephalitis. Small deal. Narrow indication. Big implication....
Genetically Informed ALS Therapies Extend Beyond Mutation‑Specific Targets
Nice ALS market map 👇 When precision approaches go broad….looks like yes that can happen. “…a third category being overlooked: 28 programs that are genetically informed but not mutation-restricted. Examples: drugs targeting TDP-43 protein clumps or repeat RNA toxicity. These mechanisms...
Milestone‑Heavy PD‑L1×VEGF Deals Signal Low Conviction
PD(L1)xVEGF the Keytruda replacement? The deal making market is clearly not pricing it that way. 🗣️“We want exposure to a hot mechanism, but we want most of the price contingent on Phase 2/3 and commercial proof.” Great analysis below...
AstraZeneca Launches First TROP2 NMR‑guided Phase 3 NSCLC Trial
👀 Real precision medicine from $AZN $DSNKY TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer “…TROPION-Lung17 is the first phase 3 clinical trial to prospectively enroll patients with tumors...
Eliminate Uncertainty to Boost Investor Confidence and XBI
Good dialog - worth the 3.5min listen 👂 TLDR - investors do not like uncertainty. Macro uncertainty, technical uncertainty, commercial uncertainty. Remove uncertainty and number go up $XBI
Pharma Accelerates PD1‑VEGF Combo Trials Across Major Players
Expect BIG activity from pharma with PD1xVEGF combos… $SMMT Announces Clinical Trial Collaboration with $GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) $PFE has already telegraphed (and started to operationalize) the same playbook. https://t.co/JTY2cuJtMG https://t.co/0zCI8zFouB
Checklist to Spot Viable Cytokine Bispecifics Amid Hype
The Next Generation of Multi-Functional I&I Therapeutics | Ep. 903 How to Pick Winners From a Crowded Cytokine War Bispecifics are everywhere, China biotech is running every combo possible including the ones you have not thought of yet. Trispecifics are next, and...
Tissue‑resident Macrophages Drive Cardioprotection, Not Tolerance
1/ 💡While much of the immunology field is fixated on immune reset in B cells and autoimmunity, a quieter version of the same idea is emerging in cardio-immunology. 🫀 Except we are not talking about lymphocytes. This is all about tissue-resident macrophages. And...
Biotech Deal Surge: Wnt, NLRP3, GLP‑1, and More
Your Weekly Biotech News Fix | Ep. 901 Designed to be consumed as a quick scroll 🧬 Parabilis - $305M Wnt bet 🔥 $LLY - Buys $VTYX (NLRP3) 🎯 $PFE - Cartography antigen deal 🧲 $AMGN - Dark Blue acquisition 🦠 $GSK / $IONS - HBV...
ASND Combo Shows Robust Growth, Heads to Phase 3
$ASND -2.5% Looks approvable (priority review; class precedent). Combo = upside optionality, not the label. COACH Wk-52 open-label Ph2 (n=21) CNP + hGH >AGV: 8.8 (naïve) / 8.42 cm/yr (prior-CNP), >97th pct vs avg-stature >Z-score: +1.02 / +0.86; proportionality/arm-span up; bone age “consistent” >AEs...
UniQure Secures FDA Type A Meeting
$QURE +13% uniQure Announces Type A Meeting Scheduled with FDA 🍿 uniQure Announces Type A Meeting Scheduled with FDA https://t.co/iqZkaNYD7Z https://t.co/lRcR6vgV0D
Market Unconvinced: KYRS Needs Functional Data
$KYRS +1% Nice science, market not convinced. KB407 shows delivery + CFTR protein in bronchoscopic biopsies, but no sweat chloride/NPD/FEV1. End of day, PD != clinical translation. Also a crowded CF GTx race = priced in. $FDMT 4D-710 (ppFEV1/LCI signals),...
JPM Acts as Audit, Reveals Biotech Translation Friction
JPM Isn’t a Conference. It’s an Audit. What 1,000 companies and 6 years of data quietly tell you about biotech translation. Part 1. Why you should care. JPM decides who looks fundable before a single new dataset drops. That sounds backward, but it...
Investors Now Require Clean Data and Clear Milestones
From Proof to Payoff | Ep. 900 2025 changed biotech translation. Capital came back with rules. No data, no money. Clean data, financing opens. If your next readout doesn’t force a decision, you stall, no matter how pretty the biology looks. What the market pays for...
Oral MRT‑8102 Shows Rapid Biomarker Drop, Upside Remains
$GLUE +45% MRT-8102 delivers eye-catching 4-week biomarker win with clean early safety and the convenience of an oral approach. MRT-8102 degrades NEK7, a scaffolding protein essential for NLRP3 inflammasome assembly, shutting down upstream activation of IL-1β/IL-18 and downstream IL-6/hsCRP, which...
